Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Artemis Therapeutics, Inc.ATMS · Entity 124649 | Chief Executive Officer | March 15, 2018 | March 19, 2018 |
| Lineage Cell Therapeutics, Inc.LCTX · Entity 6045 | Director · President and CEO | March 12, 2026 | March 12, 2026 |
| Savara IncMSTX · Entity 4900 | Director · CEO and Director | January 20, 2017 | January 23, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Artemis Therapeutics, Inc.
Report date March 15, 2018 · Filed March 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2028-03-15 | Direct | 48,528 |
Reported balance
After 2018-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-15 · Grant · Acquired 48,528 · Balance 48,528 |
Lineage Cell Therapeutics, Inc.
Report date March 12, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 255,516 |
Reported balance
After 2026-03-12 transaction · row 1
1 source rowRow 1 · 2026-03-12 · Purchase · Acquired 15,000 · Balance 255,516 F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.61 to $1.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 1. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.61 to $1.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 1.
Savara Inc
Report date January 20, 2017 · Filed January 23, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,368,194 |
Reported balance
After 2017-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-20 · Grant · Acquired 2,368,194 · Balance 2,368,194 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017). |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2026 Filed Mar 12, 2026 20:05 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | PurchaseCommon Shares | 15,000 | $1.63 | $24,375.00 |
DisclosureSEC source: 0001193125-26-104106 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,516 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.61 to $1.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 1. Read SEC document |
| March 05, 2026 Filed Mar 7, 2026 00:51 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,250,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001193125-26-097185 · ownership.xml · derivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,250,000 Underlying: Common Shares · 3,250,000 shares Expires 2036-03-05 F1 · derivative.exercise_date: One quarter of the options shall vest on March 5, 2027, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| February 11, 2026 Filed Feb 14, 2026 00:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 31,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-052021 · ownership.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 31,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted 124,997 RSUs on February 11, 2022, that vested with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026. F4 · derivative.expiration_date: The Reporting Person was granted 124,997 RSUs on February 11, 2022, that vested with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026. Read SEC document |
| February 11, 2026 Filed Feb 14, 2026 00:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares | 12,869 | $1.80 | $23,164.20 |
DisclosureSEC source: 0001193125-26-052021 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,516 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 31,250 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| February 11, 2026 Filed Feb 14, 2026 00:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares | 31,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-052021 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F1 · price: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| December 19, 2025 Filed Dec 20, 2025 02:55 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares | 334 | $1.68 | $561.12 |
DisclosureSEC source: 0001193125-25-327280 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,135 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 8,925 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in the issuer's common shares that have not vested as of the date hereof nor common shares that may be acquired upon the exercise of certain stock options outstanding as of the date hereof. Read SEC document |
| December 19, 2025 Filed Dec 20, 2025 02:55 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantCommon Shares | 8,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-327280 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,469 F1 · shares: Shares earned by the Reporting Person upon the vesting of a portion of restricted stock units ("RSUs") granted to the Reporting Person on February 11, 2022 the vesting of which was subject to the achievement of certain performance conditions. RSUs are settled in common shares on a one-for-one basis. F1 · price: Shares earned by the Reporting Person upon the vesting of a portion of restricted stock units ("RSUs") granted to the Reporting Person on February 11, 2022 the vesting of which was subject to the achievement of certain performance conditions. RSUs are settled in common shares on a one-for-one basis. F2 · balance_after: Does not include RSUs that may be settled in the issuer's common shares that have not vested as of the date hereof nor common shares that may be acquired upon the exercise of certain stock options outstanding as of the date hereof. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,300,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0000950170-25-038117 · ownership.xml · derivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,300,000 Underlying: Common Shares · 2,300,000 shares Expires 2035-03-10 F1 · derivative.exercise_date: One quarter of the options shall vest on March 10, 2026, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 21:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 31,249 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-018887 · ownership.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Shares · 31,249 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted 124,997 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026. F4 · derivative.expiration_date: The Reporting Person was granted 124,997 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 21:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares | 12,547 | $0.65 | $8,155.55 |
DisclosureSEC source: 0000950170-25-018887 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,544 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 31,249 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 21:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares | 31,249 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-018887 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F1 · price: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 14:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | PurchaseCommon Shares | 40,000 | $0.60 | $24,000.00 |
DisclosureSEC source: 0000950170-24-129972 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,842 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6046 to $0.6071, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 1. Read SEC document |
| May 24, 2024 Filed May 28, 2024 13:11 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | PurchaseCommon Shares | 10,000 | $1.05 | $10,500.00 |
DisclosureSEC source: 0000950170-24-064896 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,842 F1 · price: The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.05 to not more than $1.06. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 21:05 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,900,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001493152-24-009382 · ownership.xml · derivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,900,000 Underlying: Common Shares · 1,900,000 shares Expires 2034-03-07 F1 · derivative.exercise_date: One quarter of the options shall vest on March 7, 2025, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| February 11, 2024 Filed Feb 13, 2024 02:27 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 31,249 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-005942 · ownership.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,499 Underlying: Common Shares · 31,249 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted 124,997 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026. F4 · derivative.expiration_date: The Reporting Person was granted 124,997 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026. Read SEC document |
| February 11, 2024 Filed Feb 13, 2024 02:27 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 12,806 | $1.08 | $13,830.48 |
DisclosureSEC source: 0001493152-24-005942 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,842 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 31,249 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| February 11, 2024 Filed Feb 13, 2024 02:27 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 31,249 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-005942 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F1 · price: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| March 09, 2023 Filed Mar 11, 2023 00:03 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,900,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001493152-23-007306 · ownership.xml · derivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900,000 Underlying: Common Shares · 1,900,000 shares Expires 2033-03-09 F1 · derivative.exercise_date: One quarter of the options shall vest on March 9, 2024, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:15 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 31,249 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-004898 · ownership.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,748 Underlying: Common Shares · 31,249 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter. F4 · derivative.expiration_date: The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:15 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 12,744 | $1.35 | $17,204.40 |
DisclosureSEC source: 0001493152-23-004898 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,399 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 31,249 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:15 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 31,249 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-004898 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F1 · price: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| June 30, 2022 Filed Jun 30, 2022 21:57 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 15,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-018271 · ownership.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 15,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. F4 · derivative.expiration_date: The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. Read SEC document |
| June 30, 2022 Filed Jun 30, 2022 21:57 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 5,343 | $1.58 | $8,441.94 |
DisclosureSEC source: 0001493152-22-018271 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,894 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report. Read SEC document |
| June 30, 2022 Filed Jun 30, 2022 21:57 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 15,450 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-018271 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. RSUs convert into common shares on a one-for-one basis. F1 · price: Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. RSUs convert into common shares on a one-for-one basis. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:05 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 15,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-009000 · ownership.xml · derivative · entry 4 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,450 Underlying: Common Shares · 15,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. F5 · derivative.expiration_date: The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:05 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | PurchaseCommon Shares, no par value | 6,400 | $1.53 | $9,792.00 |
DisclosureSEC source: 0001493152-22-009000 · ownership.xml · nonDerivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,787 F4 · price: The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.52 to not more than $1.54. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:05 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 5,343 | $1.54 | $8,228.22 |
DisclosureSEC source: 0001493152-22-009000 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,387 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:05 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 15,450 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-009000 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. RSUs convert into common shares on a one-for-one basis. F1 · price: Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. RSUs convert into common shares on a one-for-one basis. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report. Read SEC document |
| March 25, 2022 Filed Mar 28, 2022 23:22 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | PurchaseCommon Shares, no par value | 5,250 | $1.38 | $7,245.00 |
DisclosureSEC source: 0001493152-22-007925 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,280 F1 · price: The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.3795 to not more than $1.3800. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range. Read SEC document |
| March 10, 2022 Filed Mar 12, 2022 01:45 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantRestricted Stock Units · Derivative | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-006699 · ownership.xml · derivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Shares · 300,000 shares Expires not disclosed F2 · derivative.exercise_price: Grant of restricted stock units under Lineage's 2021 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one Common Share. F3 · derivative.exercise_date: One-third of the shares will vest on or prior to March 9, 2023, and the second and third anniversaries of such date, upon the achievement of certain per share performance targets, calculated based on the trailing 20 trading day volume weighted average price of the Company's common stock as of the date of determination. F3 · derivative.expiration_date: One-third of the shares will vest on or prior to March 9, 2023, and the second and third anniversaries of such date, upon the achievement of certain per share performance targets, calculated based on the trailing 20 trading day volume weighted average price of the Company's common stock as of the date of determination. Read SEC document |
| March 10, 2022 Filed Mar 12, 2022 01:45 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,250,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001493152-22-006699 · ownership.xml · derivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Shares · 1,250,000 shares Expires 2032-03-10 F1 · derivative.exercise_date: One quarter of the options shall vest on March 10, 2023, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 00:38 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantRestricted Stock Units · Derivative | 124,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-004714 · ownership.xml · derivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,997 Underlying: Common Shares · 124,997 shares Expires not disclosed F1 · derivative.exercise_price: Grant of restricted stock units under Lineage's 2021 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one Common Share. F2 · derivative.exercise_date: Subject to continuous service, vests in four equal annual installments beginning on February 11, 2023. F2 · derivative.expiration_date: Subject to continuous service, vests in four equal annual installments beginning on February 11, 2023. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 21:25 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 15,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-000116 · ownership.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,900 Underlying: Common Shares · 15,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. F4 · derivative.expiration_date: The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 21:25 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 5,343 | $2.45 | $13,090.35 |
DisclosureSEC source: 0001493152-22-000116 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,030 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include common shares of the issuer that may be acquired upon settlement of RSUs that have not vested as of the date of this filing or upon the exercise of stock options outstanding as of the date of this filing. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 21:25 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 15,450 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-000116 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. Upon settlement, RSUs convert into common shares of the issuer on a one-for-one basis. F1 · price: Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. Upon settlement, RSUs convert into common shares of the issuer on a one-for-one basis. F2 · balance_after: Does not include common shares of the issuer that may be acquired upon settlement of RSUs that have not vested as of the date of this filing or upon the exercise of stock options outstanding as of the date of this filing. Read SEC document |
| September 30, 2021 Filed Oct 12, 2021 20:27 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 15,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-025197 · ownership.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,350 Underlying: Common Shares · 15,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. F4 · derivative.expiration_date: The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. Read SEC document |
| September 30, 2021 Filed Oct 12, 2021 20:27 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 5,343 | $2.52 | $13,464.36 |
DisclosureSEC source: 0001493152-21-025197 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,923 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include common shares of the issuer that may be acquired upon settlement of RSUs that have not vested as of the date of this filing or upon the exercise of stock options outstanding as of the date of this filing. Read SEC document |
| September 30, 2021 Filed Oct 12, 2021 20:27 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 15,450 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-025197 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. Upon settlement, RSUs convert into common shares of the issuer on a one-for-one basis. F1 · price: Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. Upon settlement, RSUs convert into common shares of the issuer on a one-for-one basis. F2 · balance_after: Does not include common shares of the issuer that may be acquired upon settlement of RSUs that have not vested as of the date of this filing or upon the exercise of stock options outstanding as of the date of this filing. Read SEC document |
| June 30, 2021 Filed Jun 30, 2021 22:42 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 15,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-015778 · ownership.xml · derivative · entry 6 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,800 Underlying: Common Shares · 15,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. F7 · derivative.expiration_date: The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. Read SEC document |
| June 30, 2021 Filed Jun 30, 2021 22:42 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 5,343 | $2.85 | $15,227.55 |
DisclosureSEC source: 0001493152-21-015778 · ownership.xml · nonDerivative · entry 4 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,816 F5 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F1 · balance_after: Does not include restricted stock units ("RSUs") that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report. Read SEC document |
| June 30, 2021 Filed Jun 30, 2021 22:42 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 15,450 | $2.85 | $44,032.50 |
DisclosureSEC source: 0001493152-21-015778 · ownership.xml · nonDerivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Shares earned by the reporting person as a result of the vesting of a portion of RSUs granted to the reporting person on September 17, 2018. RSUs convert into common shares on a one-for-one basis. F1 · balance_after: Does not include restricted stock units ("RSUs") that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:42 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001493152-21-015778 · ownership.xml · derivative · entry 5 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 933,300 Underlying: Common Shares · 300,000 shares Expires 2030-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The reporting person was granted options on March 17, 2020, with an exercise price of $0.6919 per share to purchase up to 1,233,300 shares. One quarter of the options vested and became exercisable on March 17, 2021, the first anniversary of the grant date, and the balance vest in 36 monthly installments thereafter upon completion of each month of the reporting person's continuous employment. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:42 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | SaleCommon Shares, no par value | 450,000 | $2.87 | $1,291,500.00 |
DisclosureSEC source: 0001493152-21-015778 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,709 F2 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. F3 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $2.81 to not more than $2.93. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. F1 · balance_after: Does not include restricted stock units ("RSUs") that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:42 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 300,000 | $0.69 | $207,570.00 |
DisclosureSEC source: 0001493152-21-015778 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Does not include restricted stock units ("RSUs") that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 00:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 15,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-007794 · ownership.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,250 Underlying: Common Shares · 15,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted RSUs on September 17, 2018 that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. F4 · derivative.expiration_date: The Reporting Person was granted RSUs on September 17, 2018 that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 00:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 5,343 | $2.35 | $12,556.05 |
DisclosureSEC source: 0001493152-21-007794 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,709 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 00:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 15,450 | $2.35 | $36,307.50 |
DisclosureSEC source: 0001493152-21-007794 · ownership.xml · nonDerivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on September 17, 2018. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,165,100 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001493152-21-006274 · ownership.xml · derivative · entry 1 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,165,100 Underlying: Common Shares · 1,165,100 shares Expires 2031-03-15 F1 · derivative.exercise_date: One quarter of the options shall vest on March 15, 2022 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| December 31, 2020 Filed Dec 31, 2020 22:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 15,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-024692 · ownership.xml · derivative · entry 3 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,700 Underlying: Common Shares · 15,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted RSUs on September 17, 2018 that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. F4 · derivative.expiration_date: The Reporting Person was granted RSUs on September 17, 2018 that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. Read SEC document |
| December 31, 2020 Filed Dec 31, 2020 22:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 5,343 | $1.76 | $9,403.68 |
DisclosureSEC source: 0001493152-20-024692 · ownership.xml · nonDerivative · entry 2 Culley Brian M · CIK 0001310683 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,602 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.